Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Oruka Therapeutics, Inc. - Common Stock
(NQ:
ORKA
)
20.31
-0.45 (-2.17%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Oruka Therapeutics, Inc. - Common Stock
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
December 19, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
December 18, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
November 19, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 13, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Oruka Therapeutics to Present at Multiple November Investor Conferences
November 04, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
September 25, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Oruka Therapeutics Announces $200 Million Private Placement
September 12, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
September 12, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.